Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression

Who May Qualify: - Adults diagnosed with dry AMD at an early or intermediate stage, classified according to the Beckman Classification and confirmed by fundus photography: (1) Early AMD: medium drusen (\>63 μm and ≤125 μm) without AMD-related pigmentary abnormalities; (2) Intermediate AMD: large drusen (\>125 μm), with or without AMD-related pigmentary abnormalities. - Willing to stop supplementation of omega-3 fatty acids, choline, or astaxanthin. - Willing to sign the willing to sign a consent form, and willing to attend follow-up visits for at least 3 months. Who Should NOT Join This Trial: - Any eye with disease that would interfere with the fundus examinations. - Eye with choroidal neovascularization (CNV), geographic atrophy (GA), or high myopia. - Surgeries that may interfere with AMD evaluation. - Long-term use of any medications that are associated with retinal or neural toxicities. - History of supplementation with lutein, zeaxanthin, DHA, or EPA, unless a wash-out period of at least 8 weeks is completed prior to enrollment. - Intraocular pressure more than 26 mmHg. - Received cataract surgery in 3 months. - Other conditions: subjects with severe systemic diseases; any condition that causes high risk of drop-out, or low compliance, for instance cognition disorder; have been involved in other trial that interfere with the current visit plan; taking other angiogenesis Inhibitors drugs for treating cancer. - Other conditions not suitable for the current study. Always talk to your doctor about whether this trial is right for you.